1. Home
  2. IMNN vs HTCR Comparison

IMNN vs HTCR Comparison

Compare IMNN & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • HTCR
  • Stock Information
  • Founded
  • IMNN 1982
  • HTCR 2009
  • Country
  • IMNN United States
  • HTCR Japan
  • Employees
  • IMNN N/A
  • HTCR N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • HTCR EDP Services
  • Sector
  • IMNN Health Care
  • HTCR Technology
  • Exchange
  • IMNN Nasdaq
  • HTCR Nasdaq
  • Market Cap
  • IMNN 12.1M
  • HTCR 10.3M
  • IPO Year
  • IMNN 1985
  • HTCR 2022
  • Fundamental
  • Price
  • IMNN $7.61
  • HTCR $0.47
  • Analyst Decision
  • IMNN Buy
  • HTCR
  • Analyst Count
  • IMNN 2
  • HTCR 0
  • Target Price
  • IMNN $210.00
  • HTCR N/A
  • AVG Volume (30 Days)
  • IMNN 405.2K
  • HTCR 94.6K
  • Earning Date
  • IMNN 08-05-2025
  • HTCR 08-13-2025
  • Dividend Yield
  • IMNN N/A
  • HTCR 4.13%
  • EPS Growth
  • IMNN N/A
  • HTCR N/A
  • EPS
  • IMNN N/A
  • HTCR N/A
  • Revenue
  • IMNN N/A
  • HTCR $28,947,523.00
  • Revenue This Year
  • IMNN N/A
  • HTCR N/A
  • Revenue Next Year
  • IMNN N/A
  • HTCR $8.59
  • P/E Ratio
  • IMNN N/A
  • HTCR N/A
  • Revenue Growth
  • IMNN N/A
  • HTCR 59.42
  • 52 Week Low
  • IMNN $5.55
  • HTCR $0.39
  • 52 Week High
  • IMNN $54.75
  • HTCR $3.38
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 38.74
  • HTCR 45.86
  • Support Level
  • IMNN $6.51
  • HTCR $0.48
  • Resistance Level
  • IMNN $8.10
  • HTCR $0.53
  • Average True Range (ATR)
  • IMNN 1.32
  • HTCR 0.04
  • MACD
  • IMNN 0.20
  • HTCR 0.01
  • Stochastic Oscillator
  • IMNN 20.04
  • HTCR 32.79

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

Share on Social Networks: